Tirzepatide's Benefits Go Beyond GLP-1 Agonist Effects

Tirzepatide's agonist effect on GIP receptors of isolated pancreatic islet cells appears responsible for a good portion of the drug's effects beyond its GLP-1 receptor agonism.
Medscape Medical News

source https://www.medscape.com/viewarticle/993002?src=rss

Comments

Popular posts from this blog

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

New AAFP practice guideline sets blood pressure targets for adults with hypertension